CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM024336
Első szerző:Terzano, Claudio
Cím:Corticosteroids administered by nebulization to children with bronchial asthma / C. Terzano, L. Barkai, G. Cremonesi
Dátum:2001
Megjegyzések:Inhaled corticosteroids are recommended for long-term control of asthma in children, and nebulization simplifies administration to patients who lack hand-to-lung coordination. Information on the efficacy and safety of nebulized corticosteroids in children with mild to moderate asthma is limited, however, and comparison between corticosteroids is lacking. One hundred thirty-three patients 6 to 14 years of age with bronchial asthma were randomly assigned to receive flunisolide 500 ?g or budesonide 500 ?g, both administered twice daily by nebulizer for 4 weeks. Morning peak expiratory flow rate (primary efficacy endpoint) increased significantly from baseline (P<.001) with both medications (P = NS between treatments). Use of salbutamol as rescue medication decreased by 82.6% with flunisolide and by 82.7% with budesonide; respective decreases in asthma score were 78.8% and 82.3% (P<.001 vs baseline, P = NS between treatments). Only flunisolide reduced the number of nocturnal awakenings (P<.001). Ten patients in the flunisolide group and 12 in the budesonide group reported adverse events, none of which required discontinuation of treatment. In children with asthma, nebulized corticosteroids are effective and have good safety and tolerability profiles. Flunisolide and budesonide seem to produce equivalent clinical responses.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Statistics, Nonparametric
Nebulizers and Vaporizers
Male
Humans
Fluocinolone Acetonide
Female
Child
Budesonide
Asthma
Anti-Inflammatory Agents
Adolescent
wakefulness
randomized controlled trial
peak expiratory flow
nebulizer
nebulization
multicenter study
major clinical study
long term care
human
flowmeter
drug tolerability
drug safety
drug induced disease
drug efficacy
disease severity
controlled study
controlled clinical trial
clinical trial
childhood disease
ARTICLE
soluzione
salbutamol
respules
nisolid
Flunisolide
corticosteroid
Nebulized drugs
Inhaled corticosteroids
Megjelenés:Advances in Therapy. - 18 : 6 (2001), p. 253-260. -
További szerzők:Barkai László (1958-) (gyermekgyógyász) Cremonesi, G.
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:

2.

001-es BibID:BIBFORM024335
Első szerző:Terzano, Claudio
Cím:Beclomethasone dipropionate versus budesonide inhalation suspension in children with mild to moderate persistent asthma / C. Terzano, L. Allegra, L. Barkai, G. Cremonesi
Dátum:2000
Megjegyzések:Inhaled steroids are the most effective long-term treatment of persistent asthma but many children are unable to use correctly the available inhalers. Administration of nebulized corticosteroids has some advantages over the administration with pressurised metered-dose inhalers (pMDIs). The objective of this multicenter randomised study was to compare the efficacy and tolerability of nebulized corticosteroids in paediatric patients with asthma. 127 patients aged ?6 and ? 14 years with a diagnosis of mild to moderate persistent asthma (PEFR % predicted > 50% and < 85%) and positive response to the reversibility test were randomized. The patients were assigned by randomisation to one of the two treatment groups (4 weeks): beclomethasone dipropionate (BDP) 800 ?g/daily b.i.d. (n=66) or budesonide (BUD) 1000 ?g/daily b.i.d. (n=61) both administered by nebulizer. The primary efficacy end point was the final mean of PEFR measured at clinical visit (clinic PEFR). In the BDP group clinic PEFR increased from 177.5 ? 80 L/min to 246.6 ? 84.2 L/min (p<0.001vs baseline), while in the BUD group the increase was from 180.4 ? 77.8 L/min to 260.9 ? 84.1 L/min (p<0.001 vs baseline) (NS between treatments). FEV<sub>1</sub> (% predicted) increased from 77.8% to 92.7% (p<0.001 vs baseline) and from 74.1% to 95.9% (p<0.001 vs baseline) in BDP and BUD group respectively (NS between treatments). Patients reduced the use of salbutamol rescue medication by 76% and 81% in BDP and BUD group respectively (p<0.001 vs baseline, NS between treatments). 4 patients in the BDP group and 2 in the BUD group reported adverse events (AEs). AEs were mild to moderate and never there was the need to discontinue the treatments. In conclusion the results of this study demonstrate that both BDP (800 ?g/daily) and BUD (1000 ?g/daily) administered by nebulization are effective and with a acceptable safety and tolerability profile.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
SUSPENSIONS
Statistics, Nonparametric
Male
Humans
Female
Confidence Intervals
Child
Chi-Square Distribution
Budesonide
Bronchodilator Agents
Beclomethasone
Asthma
Anti-Asthmatic Agents
Analysis of Variance
Adolescent
Administration, Inhalation
suspension
sinusitis
randomized controlled trial
peak expiratory flow
otitis
nebulization
multicenter study
medical nebulizer
major clinical study
human
hoarseness
Forced Expiratory Volume
drug tolerability
drug safety
drug formulation
drug efficacy
drug delivery system
controlled study
controlled clinical trial
clinical trial
ARTICLE
allergic rhinitis
salbutamol
prednisone
leukotriene receptor blocking agent
cromoglycate disodium
corticosteroid derivative
cholinergic receptor blocking agent
bronchodilating agent
beta adrenergic receptor blocking agent
beta 2 adrenergic receptor stimulating agent
beclometasone dipropionate
antihistaminic agent
Nebulized drugs
Beclomethasone dipropionate
Megjelenés:European Review for Medical and Pharmacological Sciences. - 5 : 1 (2000), p. 17-24. -
További szerzők:Allegra, L. Barkai László (1958-) (gyermekgyógyász) Cremonesi, G.
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Szerző által megadott URL
Borító:
Rekordok letöltése1